Latest news and press releases about Aprea Therapeutics, Inc. (APRE): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors.
Price
| Price | $0.73 |
| Market Cap | $9M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.41 |
| EV / EBITDA | 0.72 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -101.27% |
| Return on Invested Capital | -100.49% |
| Return on Assets | -79.08% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · ADIL · APVO · BCDA · CELZ · GLTO · HCWB
Explore sector: Healthcare · Biotechnology
More sections of APRE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks